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Methylation patterns in CD34 positive chronic
myeloid leukemia blast crisis cells
Treatment results of chronic myeloid leukemia blast
crisis are unsatisfactory, even with second generation
tyrosine kinase inhibitors and allogeneic stem cell trans-
plantation. Loss of tumor suppressor gene activity is one
of the events that is associated with progression to blast
crisis. Next to genetic alterations, this may be related to
hypermethylation of the promoter regions of these
genes. Demethylating drugs, like decitabine and 5-azacy-
tidine, have recently become available for clinical purpos-
es and may act by reversing abnormal methylation of
chronic myeloid leukemia blast crisis. To estimate their
potential value for treatment of chronic myeloid
leukemia blast crisis, we investigated the methylation
status of the promoters of tumor suppressor genes in clin-
ical samples, using methylation specific multiplex liga-
tion-dependent probe amplification (MS-MLPA), a tech-
nique that has been demonstrated to give reliable results,
comparable to classical sodium bisulphite sequencing
based assays or methylation specific polymerase chain
reaction (MSP).1-3Methylation specific multiplex ligation-
dependent probe amplification enables simultaneous
assessment of a large number of chronic myeloid
leukemia blast crisis, requires low amounts of DNA
(unlike MSP) and is relatively inexpensive. 
After informed consent, DNA was isolated from
peripheral blood and bone marrow CD34 positive cells
(selected by AutoMACS, Miltenyi Biotec, Bergisch
Gladbach, Germany) of 19 blast crisis patients (Table 1)
and 15 newly diagnosed, untreated chronic myeloid
leukemia patients as controls. MS-MLPA was subse-
quently performed as described previously using probe
mixes ME001-Tumor suppressor-1 and ME002-Tumor
suppressor-2, which include probes targeted to the CpG
islands within the promoter regions of 35 candidate
tumor suppressor genes (Online Supplementary Table
S1).1,3
Using this technique, we observed methylation of at
least one tumor suppressor gene promoter CpG island in
all 19 blast crisis samples, with a total number of 69
methylated genes. CDH13, ESR1, IGSF4, MGMT and
CDKN2B were the genes that were most frequently
1036 haematologica | 2010; 95(6)
Letters to the Editor
Table 1. Clinical characteristics and results of MS-MLPA. Only genes that were methylated in at least one patient sample are shown. Blanks indicate unmethy-
lated promoter regions.
Pt Age Myeloid/ Interval Previous T/ BRCA CD CDH CDKN CDKN ESR FHIT GATA IGSF MGMT MSH PAX PAX RARB STK THBS TIMP TP WT total*
n. (yr) Lymphoid D/-BC 1 44 13 2A 2B 1 5 4 6 5 6 11 1 3 73 1
BC (mos) probe set 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2
number 
1 38 my 26 IM U/M M/M2 M M/M M M M/M M/M M M/M M M M M/M 14
2 44 my 43 HU U/M M 2
3 17 my 3 HU U/M U/M U/M 3
4 26 my 0 none M M U/M 3
5 71 bi3 0 none U/M U/M U/M M M/M U/M 6
6 53 my 0 none M/M M M/U M 4
7 66 ly 4 IM M/M M/M M/M U/M U/M 5
8 56 my 1 none M/M U/M 2
9 65 my 84 IM U/M U/M M/U 3
10 46 my 156 IFN/LD-AraC U/M U/M 2
11 39 my 13 IM/ID-AraC U/M U/M M 3
12 54 my 7 IM/ID-AraC; U/M U/M M/U U/M
Ida/AraC 4
13 66 my 40 IM U/M U/M U/M 3
14 59 my 46 HU/IFN U/M M 2
15 52 ly 0 none U/M 1
16 46 my 0 none U/M U/M 2
17 62 my 3 IM/ID-AraC U/M U/M M 3
18 61 my 3 HU/IFN U/M 1
19 79 u 119 u M/M M M M M U/M 6
total 1 3 15 1 5 8 3 2 7 6 1 1 2 4 1 1 2 5 1
D/: diagnosis; BC: blast crisis; U: unknown; T/: treatment; IM: imatinib; HU: hydroxyurea; IFN: interferon-alpha; LD-AraC: low-dose cytarabine; ID-AraC: intermediate dose cytarabine; Ida: idarubicin
1: blanks in this row indicate that only one probe set was used as shown in Online Supplementary Table S1. 2: M: methylated; U: unmethylated; 3: biphenotypic *: In case two probe sets for a sin-
gle gene promoter were used, the gene was scored positive when at least one probe set showed methylation; if two CpG islands tested in a single gene promoter were methylated, then counted
only once .
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methylated (Table 1). In the 15 control CML-CP samples,
only 3 individual patients had a single methylated gene,
CDH13, MGMT and MSH1, respectively. All other test-
ed genes were non-methylated (P<0.001 for difference in
number of methylated genes between CP and blast crisis,
Mann-Whitney U-test).
Thus, aberrant methylation of tumor suppressor genes
seems a common event in chronic myeloid leukemia
blast crisis. In clinical chronic myeloid leukemia samples
and chronic myeloid leukemia cell lines, methylation of
BRCA1, CDH13, CDKN2B, ESR1, FHIT and PAX6 was
demonstrated before.4-8 However, to our knowledge,
aberrant methylation of CD44, GATA5, IGSF4, MGMT,
MSH6, PAX5, RARB, STK11, THBS1, TP73 and WT1 in
chronic myeloid leukemia blast crisis has not been report-
ed previously. Importantly, as we used CD34 positive
progenitor cells in all samples (blast crisis as well as CP),
methylation appears to be an acquired event during or
preceding transformation of the disease and not just the
result of increasing numbers of progenitor cells that had
methylated genes from the start in CP, but that were
obscured by the admixture of more differentiated cells
with non-methylated promoters. As we did not have at
our disposal CD34 positive samples from diagnosis and
blast crisis of the same patients, this hypothesis cannot,
however, be proven. 
The high number of methylated genes in blast crisis
may suggest that aberrant methylation is a non-specific,
global process that is a feature of advanced phase chron-
ic myeloid leukemia, at least in a subset of patients.
Possibly, this may be related to increased expression of
dimethyltransferases, as was demonstrated for DNMT1,
3A and 3B in chronic myeloid leukemia blast crisis sam-
ples when compared with normal bone marrow.9 In the
mononuclear cell fraction of chronic myeloid leukemia
CP samples, no increase in DNMT levels was observed.
The mechanism behind the upregulation of these
enzymes is unknown.
Restoring tumor suppressor gene expression by
demethylating treatment may be a rational therapeutic
strategy. A few clinical studies assessing the efficacy of
demethylating treatment in chronic myeloid leukemia
have been published. Kantarjian et al. investigated treat-
ment of chronic myeloid leukemia patients with
decitabine in different phases of the disease.10 Responses
were superior in early phase chronic myeloid leukemia
compared to more advanced phases, while myelosup-
pression was the most important adverse effect. The
combination of decitabine with imatinib seemed to have
only modest activity in a second, phase II study.11 In
patients who responded to the combination, there was a
lesser decrease of global DNA methylation than in the
non-responders. The results of both studies call into
question whether the observed clinical effect relates to
reduction of methylation. Further studies are warranted
to determine if, indeed, hypomethylating activity is their
main mechanism of action.
In conclusion, the progenitor cell fraction in chronic
myeloid leukemia blast crisis clearly shows more exten-
sive methylation of putative tumor suppressor genes than
in CP, where methylation is almost absent. Aberrant
methylation of several of the tumor suppressor genes
that we detected has not been previously reported. Our
results suggest that hypermethylation of tumor suppres-
sor genes may be a therapeutic target. However, more
extensive pre-clinical and clinical studies incorporating
demethylating agents are needed to assess their thera-
peutic role in chronic myeloid leukemia blast crisis.
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